Royalty Pharma CFO converts interests into 250K shares
The exchange terms provide for each RPI US LP interest to convert into ten Class B Interests, each exchangeable for one Class A Ordinary Share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported that, on November 6, 2026, TPC RP 2021, LLC and TPC RP, LLC exchanged 15,000 and 10,000 RPI US Partners 2019, LP interests, respectively, for 150,000 and 100,000 Class A Ordinary Shares; the exchange involved no additional value. Following the conversions, the entities were reported with 102,526 and 473,942 LP interests, respectively. On November 4, 2026, TPC RP EPA1 LLC acquired 7,122 Class A Ordinary Shares in settlement of Equity Performance Awards, with 7,122 shares reported following the acquisition. A separate holding lists 43,350 LP interests held through TPC ICAI, LLC, exchangeable for 433,500 Class A Ordinary Shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | LP interests in RPI US Partners 2019, LP F2, F3 | 15,000 | $0.00 | $0.00 |
| Conversion | LP interests in RPI US Partners 2019, LP F2, F3 | 10,000 | $0.00 | $0.00 |
| Conversion | Class A Ordinary Shares F2 | 150,000 | $0.00 | $0.00 |
| Conversion | Class A Ordinary Shares F2 | 100,000 | $0.00 | $0.00 |
| Grant/Award | Class A Ordinary Shares F1 | 7,122 | $0.00 | $0.00 |
| Holding | LP interests in RPI US Partners 2019, LP F3 | -- | -- | -- |
| Holding | Class A Ordinary Shares | -- | -- | -- |
| Holding | Class A Ordinary Shares | -- | -- | -- |
| Holding | Class A Ordinary Shares | -- | -- | -- |
| Holding | Class A Ordinary Shares | -- | -- | -- |
Footnotes (3)
- F1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
- F2. These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("RPH"). Each Class B Interest in RPH so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with the exchange.
- F3. Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in RPH at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in RPH issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.
Key Figures
Key Terms
Equity Performance Awards financial
RPI US LP Interest financial
Class B Interests financial
Amended and Restated Exchange Agreement regulatory
Rule 16b-3 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were the terms of RPRX's reported LP-interest exchange?
AI-generated analysis. How Rhea-AI works. Not financial advice.
